Scientists found that aggressive lung cancer cells create their own electrical network, helping them spread. This unique ...

NEW YORK – Cancer diagnostics firm AccuStem Sciences announced on Tuesday that it has acquired the license for the proprietary MicroRNA Signature Classifier (MSC) test for lung cancer screening from ...

In another case study, CyPath® Lung helped physicians identify and treat a recurrence of breast cancer in a high-risk patient.

Clinical stage diagnostics company AccuStem Sciences has acquired the licence for the microRNA Signature Classifier (MSC) ...

Qure.ai, a global leader in artificial intelligence (AI) for healthcare, today announced the launch of India’s first AI-led ...

Researchers found that adherence to the first and second annual screenings was 61% and 51%, respectively, with higher lung ...

Real-time index price for Nasdaq Other Finance Index (OFIN), along with buy or sell indicators, analysis, charts, historical ...

AccuStem pursuing strategic commercialization plan intending to launch the MSC test in the US in 2026LONDON and PHOENIX, Ariz., March 18, 2025 ...

The following is a summary of "Interventions To Improve Adherence To Clinical Guidelines For The Management And Follow-Up Of ...

It invested in a robotic, noninvasive technology for biopsies of hard-to-reach lesions in the lungs and to remove suspected ...

Good Samaritan announced in a recent press release the addition of the Ion Endoluminal System, a state-of-the-art ...

Robin Lindaman is stubborn. The language she used to describe herself was a little more colorful, but stubborn fits. She has ...